Mineralys Therapeutics (MLYS) Earnings Date & Reports
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
MLYS is expected to report earnings to rise 80.77% to -93 cents per share on March 18
Q4'25
Est.
$-0.94
Q3'25
Beat
by $0.44
Q2'25
Beat
by $0.40
Q1'25
Beat
by $0.29
Q4'24
Missed
by $0.27
The last earnings report on November 10 showed earnings per share of -51 cents, beating the estimate of -95 cents. With 665.23K shares outstanding, the current market capitalization sits at 2.96B.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. MLYS showed earnings on November 10, 2025. You can read more about the earnings report here.